A Study of SPY003-207 in Healthy Volunteers

ClinicalTrials.gov ID: NCT06873724

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT06873724. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of SPY003-207 in Healthy Participants

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 1, randomized, double-blind, placebo-controlled, single dose, first in human safety, tolerability, and pharmacokinetic study of SPY003-207 in healthy participants.

Study identification

NCT ID: NCT06873724
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Spyre Therapeutics, Inc.; Industry
Enrollment: 59 participants

Conditions and interventions

Conditions

Healthy

Interventions

SPY003-207 Drug
Placebo Other

Drug · Other

Eligibility (public fields only)

Age range: 18 Years to 60 Years
Sex: All
Healthy volunteers: Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 10, 2025 (Actual)
Primary completion: Nov 18, 2026 (Estimated)
Completion: Nov 18, 2026 (Estimated)
Last update posted: Mar 20, 2026

2025 – 2026

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Spyre Site 2	Cypress	California	90630	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06873724, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 20, 2026 · Synced Nov 15, 2026